StockData
Evommune, Inc. logo

Evommune, Inc. (EVMN) stock

EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$8.02−0.60 (-6.96%)

Close on Nov 12, 2026Market cap $291.06MP/E –Yield –

Earnings

Evommune's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Dec 10, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
–
EPS, Q2 FY2026
-$0.89
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Evommune's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Dec 10, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 6, 2026after the close––-$0.89Release
Q1 FY2026ended Mar 31, 2026May 7, 2026after the close––-$0.64Release
Q4 FY2025ended Dec 31, 2025Mar 5, 2026after the close$0–-$1.43Release
Q3 FY2025ended Sep 30, 2025Dec 11, 2025after the close$10.00M–-$8.07Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Evommune has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Evommune puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Evommune filed with the SEC as exhibits to Form 8-K or 6-K

  1. Evommune Reports Third Quarter 2026 Financial Results and Provides Business Highlights
    Results
  2. Corporate Presentation November 2026 © Evommune, Inc.
    Results
  3. Evommune to Host Webcast on EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
    Update
  4. Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals
    Update
  5. Evommune Announces $30 Million Private Placement
    Update
  6. EVO570: Potential Best-in-Class VAV1 Molecular Glue Degrader JAK-like efficacy with improved safety could position VAV1 to compete broadly in established JAK markets and beyond © Evommune, Inc.
    Update
  7. Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
    Update
  8. Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
    Update
  9. Evommune Corporate Presentation September 2026 © Evommune, Inc.
    Update
  10. Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
    Update
  11. Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
    Results
  12. Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
    Update
  13. Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
    Update
  14. Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
    Results
  15. May 2026 © Evommune, Inc. Corporate Presentation
    Results

See a number that looks wrong?